Everlab raises $65m to build the next layer of preventative healthcare
The Melbourne startup says it has processed 21 million biomarker results and is now taking its AI-powered preventative care platform to the UK.
Australian healthtech startup Everlab has closed a $65 million Series A round, betting that artificial intelligence has made it economically viable to deliver the kind of personalised preventative care that once cost upwards of $50,000 a year.
The oversubscribed round was led by Airtree Ventures, with participation from European fund Plural, existing investors Left Lane Capital and b2venture, and angel investors including Australian Test cricket captain Pat Cummins.
It follows a $15 million seed round in July last year, led by global growth equity firm Left Lane Capital, and brings the three-year-old startup’s total raised to $80 million.
“We were actually not planning on raising,” said Marc Hermann, co-founder and CEO. “We’ve been very cash efficient since closing the Left Lane round. It was just that our operative business performed really well, and there were some funds that missed out last time.”
